Wilmot Cancer Institute

Congrats to Wilmot Cancer Institute's Nicole O'Dell, PhD, MLS, and Emily Hayes, MPA! They recently attended the Cancer Center Community Impact Forum in Salt Lake City with others working in community outreach at cancer centers across the country. The duo presented a poster that focused on Wilmot's Future Deaf Scientists summer internship program and how their teams engage the local Deaf community at the end-of-program student presentations and celebrations. Great job!

It's another #WilmotFlashbackFriday to celebrate 50 years since the University of Rochester established its cancer center. This photo comes from 1987 and we're sharing it in honor of spooky season 💀 But don't be afraid! This skeleton was simply a teaching tool, helping to educate the next generation of cancer clinicians and researchers.

Dr. Richard Dunne, a Wilmot Cancer Institute oncologist, worked with a team to understand cachexia, a wasting syndrome that can cause cancer patients to lose too much weight during treatment and decrease their chances of survival. Clinical trials for a medication called Ponsegromab have shown to be effective against cachexia, although more research is still needed. Dr. Dunne shared insights with the National Cancer Institute (NCI) Currents blog. #URochesterResearch https://lnkd.in/gqfp-xwH

New research from a Wilmot Cancer Institute research team shows that the tumor microenvironment alters the circadian rhythm of macrophages, impacting their ability to restrain tumor growth. Read the study in Embo Reports: https://lnkd.in/g3BGzuB5 Nice work, Amelia Knudsen-Clark, Daniel Mwangi, Juliana Cazarin, Cameron Baker, Lauren Hablitz, Matthew McCall, and Minsoo Kim! #URochesterResearch

For five years, the University of Rochester Medical Center has offered living-donor liver transplants for patients whose colorectal cancer has spread to the liver. Matthew Byrne, MD, surgery resident at URMC, was part of a group who looked back over those five years and found that transplant prolongs patients’ lives, giving them more time with family. Read the five-year report in the American Journal of Transplantation 👉 https://lnkd.in/gZcdC8yn And learn more from URMC 👉 https://lnkd.in/exKWd_BN #URochesterResearch

It's Wear Pink Day! 💗💗 Our clinical care teams and research labs are proud to support our community impacted by breast cancer and to conduct research to try to improve breast cancer treatments for patients in the future. #wearpinkday #breastcancerawarenessmonth

Exciting news! 🚨 A new study just published in the New England Journal of Medicine (NEJM Group) and led by Dr. Jonathan Friedberg reports that an immunotherapy treatment called nivolumab combined with chemo boosted the survival rate for Hodgkin lymphoma to 92%, compared to the current standard of care. That means that 9 out of 10 patients who got the immunotherapy in this clinical trial were in remission after two years. The study is important for several reasons: ➡It enrolled nearly 1,000 patients from institutions around the country, including Wilmot, some as young as 12. ➡ Investigators were trying to raise the cure rate while also reducing side effects associated with older treatments, which can include second cancers later in life and other health problems. ➡ Hodgkin lymphoma is a disease that often impacts young people and the goal was to set them on a path that will allow them to live for decades with fewer risks of harm. Ongoing basic and clinical research is what leads to cutting-edge cancer care! Read more: https://lnkd.in/guVhQ8fx #URochesterResearch

About 200 community members and UR/Wilmot employees came out to our Fifth Community Cancer Action Council (CCAC) Retreat on Friday, Oct. 11, to celebrate accomplishments and discuss priorities for improvement going forward. We talked about challenges and ideas for helping to lessen the impact that cancer has on everyone in our diverse region. It was an inspiring, meaningful day. Thank you to everyone who helped make it possible!

Community has always been a part of Wilmot Cancer Institute's 50-year mission, but in the last few years, efforts in this area have been strengthened and streamlined. Our Community Cancer Action Council (CCAC) formed in 2020 with a mission to work with communities today to lessen the impact of cancer tomorrow. The group is made up of Wilmot Cancer Institute team members, leaders from various cancer-focused organizations and community groups, as well as individual community members interested in helping reduce the negative impact of cancer. The CCAC helps to inform research priorities, increase awareness around cancer prevention, improve aspects of patient care, and more. As the group celebrates its annual CCAC Retreat on Oct. 11, we look back on the last few years of this event that has aimed to bring together members of our community. Interested in getting involved in the future? Learn more about our CCAC: https://lnkd.in/gP8SEphe #WilmotFlashbackFriday

Conventional. Complementary. Integrative. Alternative. What do these different terms mean related to medicine and cancer treatment and how can they help patients manage side effects of cancer treatment? Dr. Alissa Huston, co-medical director of the Pluta Integrative Oncology & Wellness Center, shares insights: https://lnkd.in/grY_nhX2 #WellnessWednesday